Multiple sclerosis vs Lyme disease: A case presentation to a discussant and a review of the literature

Multiple Sclerosis

Volumn 5, Issue 6, 1999, Pages 395-402

  Karussis, Dimitrios ^a   Weiner, Howard L ^b   Abramsky, Oded ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Lyme; Multiple sclerosis; Neuroborreliosis

Indexed keywords

ANTIBIOTIC AGENT; CEFTRIAXONE; METHYLPREDNISOLONE;

ADULT; ARTICLE; BRAIN BIOPSY; CASE REPORT; CEREBROSPINAL FLUID EXAMINATION; CLINICAL FEATURE; COGNITION; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG MEGADOSE; HUMAN; LYME DISEASE; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE DISEASE; POLYMERASE CHAIN REACTION;

EID: 0033401797     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/135245859900500i605     Document Type: Article

References (158)

1. Beck RW. (1992) Corticosteroid treatment of optic neuritis: a need to change treatment practices. The Optic Neuritis Study Group [editorial] [see comments]. Neurology 42: 1133-1135.
2. Beck RW et al. (1992) A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group [see comments]. N Engl J Med 326: 581-588.
3. Optic Neuritis Study Group. (1997) The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Neurology 49: 1404-1413.
4. Rudick RA et al. (1997) Management of multiple sclerosis. N Engl J Med 337: 1604-1611.
5. Kappos L et al. (1988) Cyclosporine vs azathioprine in the long-term treatment of multiple sclerosis - results of the German multicenter study. Ann Neurol 23: 56-63.
6. Ellison GW et al. (1988) Clinical experience with azathioprine: the pros. Neurology 38: 20-23.
7. Dommasch D. (1988) Comparative clinical trial of cyclosporine in multiple sclerosis: the pros. Neurology 38: 28-29.
8. Goodkin DE et al. (1995) Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis [see comments]. Ann Neurol 37: 30-40.
9. Goodkin DE et al. (1996) Low-dose oral methotrexate in chronic progressive multiple sclerosis: analyses of serial MRIs. Neurology 47, 1153-1157.
10. Sipe JC et al. (1994) Cladribine in treatment of chronic progressive multiple sclerosis [see comments]. Lancet 344, 9-13.
11. Rudge P. (1988) Cyclosporine and multiple sclerosis: the cons. Neurology 38: 29-30.
12. Silberberg DH. (1988) Azathioprine in multiple sclerosis: the cons. Neurology 38: 24-27.
13. British and Dutch Multiple Sclerosis Azathioprine Trial Group. (1988) Double-masked trial of azathioprine in multiple sclerosis. Lancet 2, 179-183.
14. The Canadian Cooperative Multiple Sclerosis Study Group. (1991) The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. [see comments]. Lancet 337: 441-446.
15. Steere AC. (1993) Lyme disease. Bull Rheum Dis 42: 4-7.
16. Evans J. (1994) Lyme disease. Curr Opin Rheumatol 6: 415-422.
17. Evans J. (1998) Lyme disease. Curr Opin Rheumatol 10: 339-346.
18. Pachner AR. (1988) Borrelia burgdorferi in the nervous system: the new 'great imitator'. Ann NY Acad Sci 539: 56-64.
19. Pachner AR. (1990) Neurological manifestations of Lyme disease. N J Med 87, 563-564.
20. Coyle PK. (1993) Neurologic complications of Lyme disease. Rheum Dis Clin North Am 19: 993-1009.
21. Garcia-Monco JC, Benach JL. (1995) Lyme neuroborreliosis. Ann Neurol 37: 691-702.
22. Haass A. (1998) Lyme neuroborreliosis. Curr Opin Neurol 11, 253-258.
23. Halperin JJ. (1995) Neuroborreliosis. Am J Med 98, 52S-56S; discussion 56S-59S.
24. Halperin JJ. (1997) Neuroborreliosis: central nervous system involvement. Semin Neurol 17: 19-24.
25. Steere AC et al. (1986) Clinical manifestations of Lyme disease. Zentralbl Bakteriol Mikrobiol Hyg [A] 263: 201-205.
26. Corral I et al. (1997) [Neurological manifestations in patients with sera positive for Borrelia burgdorferi (see comments) (published erratum appears in Neurologia 1997 May; 12(5):200)]. Neurologia 12: 2-8.
27. Ragnaud JM et al. (1995) [Neurologic manifestations of Lyme disease: Apropos of 25 cases]. Rev Med Interne 16: 487-494.
28. Schluesener HJ, Martin R, Sticht-Groh V. (1989) Autoimmunity in Lyme disease: molecular cloning of antigens recognized by antibodies in the cerebrospinal fluid. Autoimmunity 2, 323-330.
29. Wilske B et al. (1986) Intrathecal production of specific antibodies against Borrelia burgdorferi in patients with lymphocytic meningoradiculitis (Bannwarth's syndrome). J Infect Dis 153: 304-314.
30. Benke T et al. (1995) Lyme encephalopathy: long-term neuropsychological deficits years after acute neuroborreliosis. Act a Neurol Scand 91: 353-357.
31. Kaplan RF, Jones-Woodward L. (1997) Lyme encephalopathy: a neuropsychological perspective. Semi Neurol 17: 31-37.
32. Sigal LH. (1994) Persisting complaints attributed to chronic Lyme disease: possible mechanisms and implications for management [see comments]. Am J Med 96: 365-374.
33. Sigal LH. (1994) Persisting symptoms of Lyme disease-possible explanations and implications for treatment [editorial]. J Rheumatol 21: 593-595.
34. Wang WZ et al. (1995) Lyme neuroborreliosis: evidence for persistent up-regulation of Borrelia burgdorferi-reactive cells secreting interferon-gamma. Scand J Immunol 42: 694-700.
35. Aberer E, Koszik F, Silberer M. (1997) Why is chronic Lyme borreliosis chronic? Clin Infect Dis 25: (Suppl 1), S64-S70.
36. Murray R et al. (1992) Lyme neuroborreliosis manifesting as an intracranial mass lesion. Neurosurgery 30: 769-773.
37. Logigian EL et al. (1997) Reversible cerebral hypoperfusion in Lyme encephalopathy. Neurology 49, 1661-1670.
38. Fallon BA et al. (1993) Psychiatric manifestations of Lyme borreliosis. J Clin Psychiatry 54, 263-268.
39. Burdge DR, O'Hanlon DP. (1993) Experience at a referral center for patients with suspected Lyme disease in an area of nonendemicity: first 65 patients. Clin Infect Dis 16: 558-560.
40. Roelcke U et al. (1992) Untreated neuroborreliosis: Bannwarth's syndrome evolving into acute schizophrenia-like psychosis. A case report. J Neurol 239: 129-131.
41. Pennekamp A, Jaques M. (1997) [Chronic neuroborreliosis with gait ataxia and cognitive disorders]. Schweiz Rundsch Med Prax 86: 867-869.
42. Kollikowski HH et al. (1988) Chronic borrelia encephalomyeloradiculitis with severe mental disturbance: immunosuppressive versus antibiotic therapy. J Neurol 235: 140-142.
43. Garcia-Monco JC, Benach JL. (1989) The pathogenesis of Lyme disease. Rheum Dis Clin North Am 15: 711-726.
44. Garcia-Monco JC, Benach JL. (1997) Mechanisms of injury in Lyme neuroborreliosis. Semin Neurol 17: 57-62.
45. Pfister HW, Wilske B, Weber K. (1994) Lyme borreliosis: basic science and clinical aspects [see comments]. Lancet 343: 1013-1016.
46. Pachner AR, Delaney E, O'Neill T. (1995) Neuroborreliosis in the nonhuman primate: Borrelia burgdorferi persists in the central nervous system [see comments]. Ann Neurol 38: 667-669.
47. Preac-Mursic V et al. (1989) Survival of Borrelia burgdorferi in antibiotically treated patients with Lyme borreliosis. Infection 17: 355-359.
48. Oksi J et al. (1996) Inflammatory brain changes in Lyme borreliosis. A report on three patients and review of literature. Brain 119: 2143-2154.
49. Yssel H et al. (1991) Borrelia burgdorferi activates a T helper type 1-like T cell subset in Lyme arthritis. J Exp Med 174: 593-601.
50. Weigelt W, Schneider T, Lange R. (1992) Sequence homology between spirochaete flagellin and human myelin basic protein [letter]. Immunol Today 13: 279-280.
51. Ehrenstein M, Isenberg D. (1991) Autoimmunity associated with infection: leprosy, acute rheumatic fever and Lyme disease. Curr Opin Immunol 3: 930-935.
52. Pachner AR. (1996) The immune response to infectious diseases of the central nervous system: a tenuous balance. Springer Semin Immunopathol 18: 25-34.
53. Pachner AR et al. (1997) Interleukin-6 is expressed at high levels in the CNS in Lyme neuroborreliosis. Neurology 49: 147-152.
54. Sigal LH. (1997) Immunologic mechanisms in Lyme neuroborreliosis: the potential role of autoimmunity and molecular mimicry. Semin Neurol 17: 63-68.
55. Asch ES et al. (1994) Lyme disease: an infectious and postinfectious syndrome. J Rheumatol 21: 454-461.
56. Kamradt T, Krause A, Burmester GR. (1995) A role for T cells in the pathogenesis of treatment-resistant Lyme arthritis. Mol Med 1: 486-490.
57. Zbinden R et al. (1994) Comparison of two methods for detecting intrathecal synthesis of Borrelia burgdorferi-specific antibodies and PCR for diagnosis of Lyme neuroborreliosis. J Clin Microbiol 32: 1795-1798.
58. Wang ZY et al. (1993) Intrathecal synthesis of antiBorrelia burgdorferi antibodies in neuroborreliosis: a study with special emphasis on oligoclonal IgM antibody bands. Scand J Immunol 37: 369-376.
59. Roberg M et al. (1995) Intrathecal production of specific IgA antibodies in CNS infections. J Neurol 242: 390-397.
60. Kaiser R, Rauer S. (1998) Analysis of the intrathecal immune response in neuroborreliosis to a sonicate antigen and three recombinant antigens of Borrelia burgdorferi sensu stricto. Eur J Clin Microbiol Infect Dis 17: 159-166.
61. Kaiser R. (1995) Intrathecal immune response in patients with neuroborreliosis: specificity of antibodies for neuronal proteins. J Neurol 242: 319-325.
62. Kaiser R. (1995) Intrathecal immune response in neuroborreliosis: importance of cross-reactive antibodies. Int J Med Microbiol Virol Parasitol Infect Dis 282: 303-314.
63. Kaiser R, Lucking CH. (1993) Intrathecal synthesis of specific antibodies in neuroborreliosis. Comparison of different ELISA techniques and calculation methods. J Neurol Sci 118: 64-72.
64. Kaiser R et al. (1993) Intrathecal antibody synthesis in Lyme neuroborreliosis: use of recombinant p41 and a 14-kDa flagellin fragment in ELISA. J Med Microbiol 39: 290-297.
65. Kaiser R, Lucking CH. (1993) Intrathecal synthesis of IgM and IgA in neurological diseases: comparison of two formulae with isoelectric focusing. Clin Chim Acta 216: 39-51.
66. Hammers-Berggren S et al. (1993) Borrelia burgdorferi-specific intrathecal antibody production in neuroborreliosis: a follow-up study. Neurology 43: 169-175.
67. Hansen K, Lebech AM. (1991) Lyme neuroborreliosis: a new sensitive diagnostic assay for intrathecal synthesis of Borrelia burgdorferi-specific immunoglobulin G, A, and M. Ann Neurol 30: 197-205.
68. Sigal LH et al. (1986) Proliferative responses of mononuclear cells in Lyme disease. Reactivity to Borrelia burgdorferi antigens is greater in joint fluid than in blood. Arthritis Rheum 29: 761-769.
69. Hofmann H. (1996) Lyme borreliosis - problems of serological diagnosis. Infection 24: 470-472.
70. Magnarelli LA. (1995) Current status of laboratory diagnosis for Lyme disease. Am J Med 98: 10S-12S; discussion 12S-14S.
71. Issakainen J et al. (1996) Value of clinical symptoms, intrathecal specific antibody production and PCR in CSF in the diagnosis of childhood Lyme neuroborreliosis. Klin Padiatr 208: 106-109.
72. Zoller L, Cremer J, Faulde M. (1993) Western blot as a tool in the diagnosis of Lyme borreliosis. Electrophoresis 14: 937-944.
73. Beuche W, Siever A, Felgenhauer K. (1992) Specific antigen binding by activated cerebrospinal fluid B lymphocytes in acute neuroborreliosis. J Neurol 239: 322-326.
74. Ekerfelt C et al. (1998) Augmented intrathecal secretion of interferon-gamma in response to Borrelia garinii in neuroborreliosis. J Neuroimmunol 89: 177-181.
75. Zbinden R et al. (1993) [Demonstration of intrathecal antibody formation against Borrelia burgdorferi in Lyme neuroborreliosis]. Schweiz Med Wochenschr 123: 2293-2298.
76. Demaerschalck I et al. (1995) Simultaneous presence of different Borrelia burgdorferi genospecies in biological fluids of Lyme disease patients. J Clin Microbiol 33: 602-608.
77. Christen HJ et al. (1995) Evaluation of the polymerase chain reaction for the detection of Borrelia burgdorferi in cerebrospinal fluid of children with acute peripheral facial palsy. Eur J Pediatr 154: 374-377.
78. Amouriaux P et al. (1993) Polymerase chain reaction with the 30-kb circular plasmid of Borrelia burgdorferi B31 as a target for detection of the Lyme borreliosis agents in cerebrospinal fluid. Res Microbiol 144: 211-219.
79. Huppertz HI, Schmidt H, Karch H. (1993) Detection of Borrelia burgdorferi by nested polymerase chain reaction in cerebrospinal fluid and urine of children with neuroborreliosis. Eur J Pediatr 152: 414-417.
80. Keller TL, Halperin JJ, Whitman M. (1992) PCR detection of Borrelia burgdorferi DNA in cerebrospinal fluid of Lyme neuroborreliosis patients [see comments]. Neurology 42: 32-42.
81. Lebech AM, Hansen K. (1992) Detection of Borrelia burgdorferi DNA in urine samples and cerebrospinal fluid samples from patients with early and late Lyme neuroborreliosis by polymerase chain reaction. J Clin Microbiol 30: 1646-1653.
82. Nocton JJ et al. (1996) Detection of Borrelia burgdorferi DNA by polymerase chain reaction in cerebrospinal fluid in Lyme neuroborreliosis. J Infect Dis 174: 623-627.
83. Priem S et al. (1997) An optimized PCR leads to rapid and highly sensitive detection of Borrelia burgdorferi in patients with Lyme borreliosis. J Clin Microbiol 35: 685-690.
84. Schmidt BL. (1997) PCR in laboratory diagnosis of human Borrelia burgdorferi infections. Clin Microbiol Rev 10: 185-201.
85. Weller M et al. (1992) Gangliosido antibodies: a lack of diagnostic specificity and clinical utility? J Neurol 239: 455-459.
86. Stevens A, Weller M, Wietholter H. (1992) CSF and serum ganglioside antibody patterns in MS. Acta Neurol Scand 86: 485-489.
87. Sindic CJ et al. (1997) Detection of CSF-specific oligoclonal antibodies to recombinant JC virus VP1 in patients with progressive multifocal leukoencephalopathy. J Neuroimmunol 76: 100-104.
88. Noya M, Pardo J. (1997) [Diagnosis and treatment of facial palsy]. Neurologia 12: 23-30.
89. Lana-Peixoto MA. (1994) Multiple sclerosis and positive Lyme serology. Arq Neuropsiquiatr 52: 566-571.
90. Garcia-Monco JC et al. (1990) [Multiple sclerosis or Lyme disease? a diagnosis problem of exclusion]. Med Clin (Barc) 94: 685-688.
91. Enders U et al. (1993) The spectrum of immune responses to Campylobacter jejuni and glycoconjugates in Guillain-Barre syndrome and in other neuroimmunological disorders [see comments]. Ann Neurol 34: 136-144.
92. Demaerel P et al. (1995) Childhood neuroborreliosis: clinicoradiological correlation. Neuroradiology 37: 578-581.
93. Curless RG et al. (1996) Lyme neuroborreliosis masquerading as a brainstem tumor in a 15-year-old. Pediatr Neurol 15: 258-260.
94. Coyle PK, Krupp LB, Doscher C. (1993) Significance of reactive Lyme serology in multiple sclerosis. Ann Neurol 34: 745-747.
95. Fikrig E et al. (1993) Serologic response to the Borrelia burgdorferi flagellin demonstrates an epitope common to a neuroblastoma cell line. Proc Natl Acad Sci USA 90: 183-187.
96. Dai Z et al. (1993) Molecular mimicry in Lyme disease: monoclonal antibody H9724 to B. burgdorferi flagellin specifically detects chaperonin-HSP60. Biochim Biophys Acta 1181: 97-100.
97. Sigal LH. (1990) Molecular mimicry and Lyme borreliosis [letter; comment]. Ann Neurol 28: 195-196.
98. Sigal LH. (1990) Immunology of Lyme disease. N J Med 87: 567-571.
99. Weller M et al. (1992) Are CSF or serum ganglioside antibodies related to peripheral nerve demyelination in neuroborreliosis, Guillain-Barre syndrome, or chronic inflammatory demyelinating polyradiculoneuropathy? Eur Arch Psychiatry Clin Neurosci 242: 122-126.
100. Garcia-Monco JC et al. (1993) Reactivity of neuroborreliosis patients (Lyme disease) to cardiolipin and gangliosides. J Neurol Sci 117: 206-214.
101. Garcia-Monco JC, Seidman RJ, Benach JL. (1995) Experimental immunization with Borrelia burgdorferi induces development of antibodies to gangliosides. Infect Immun 63: 4130-4137.
102. Omasits M, Seiser A, Brainin M. (1990) [Recurrent and relapsing course of borreliosis of the nervous system]. Wien Klin Wochenschr 102: 4-12.
103. Comi G et al. (1993) Brain magnetic resonance imaging correlates of cognitive impairment in multiple sclerosis. J Neurol Sci 115: (Suppl), S66-S73.
104. Comi G et al. (1995) Brain MRI correlates of cognitive impairment in primary and secondary progressive multiple sclerosis. J Neurol Sci 132: 222-227.
105. Comi G et al. (1998) Neurophysiological and cognitive markers of disease evolution in multiple sclerosis. Mult Scler 4: 260-265.
106. Hohol MJ et al. (1997) Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis. Arch Neurol 54: 1018-1025.
107. Huber SJ et al. (1987) Magnetic resonance imaging correlates of dementia in multiple sclerosis. Arch Neurol 44: 732-736.
108. Huber SJ et al. (1992) Magnetic resonance imaging correlates of neuropsychological impairment in multiple sclerosis. J Neuropsychiatry Clin Neurosci 4: 152-158.
109. Kujala P et al. (1994) Automatic and controlled information processing in multiple sclerosis. Brain 117: 1115-1126.
110. Kujala P et al. (1995) Attention related performance in two cognitively different subgroups of patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 59: 77-82.
111. Kujala P, Portin R, Ruutiainen J. (1996) Language functions in incipient cognitive decline in multiple sclerosis. J Neurol Sci 141: 79-86.
112. Kujala P, Portin R, Ruutiainen J. (1996) Memory deficits and early cognitive deterioration in MS. Acta Neurol Scand 93: 329-335.
113. Kujala P, Portin R, Ruutiainen J. (1997) The progress of cognitive decline in multiple sclerosis. A controlled 3-year follow-up. Brain 120: 289-297.
114. Maurelli M et al. (1992) Neuropsychological assessment in MS: clinical, neurophysiological and neuroradiological relationships. Acta Neurol Scand 86: 124-128.
115. Steere AC et al. (1993) The overdiagnosis of Lyme disease [see comments]. Jama 269: 1812-1816.
116. Mourin S et al. (1993) [Epilepsy disclosing neuroborreliosis]. Rev Neurol 149: 489-491.
117. Silva MT et al. (1995) Neuroborreliosis as a cause of respiratory failure. J Neurol 242: 604-607.
118. Pfister HW et al. (1989) Cefotaxime vs penicillin G for acute neurologic manifestations in Lyme borreliosis. A prospective randomized study. Arch Neurol 46: 1190-1194.
119. Rohacova H et al. (1996) Ceftriaxone in the treament of Lyme neuroborreliosis. Infection 24: 88-90.
120. Wormser GP. (1997) Treatment and prevention of Lyme disease, with emphasis on antimicrobial therapy for neuroborreliosis and vaccination. Semin Neurol 17: 45-52.
121. Kalish RA, Leong JM, Steere AC. (1993) Association of treament-resistant chronic Lyme arthritis with HLA-DR4 and antibody reactivity to OspA and OspB or Borrelia burgdorferi. Infect Immun 61: 2774-2779.
122. Karlsson M et al. (1994) Comparison of intravenous penicillin G and oral doxycycline for treatment of Lyme neuroborreliosis. Neurology 44: 1203-1207.
123. Karlsson M et al. (1996) Concentrations of doxycycline and penicillin G in sera and cerebrospinal fluid of patients treated for neuroborreliosis. Antimicroh Agents Chemother 40: 1104-1107.
124. Hansen K et al. (1992) Roxithromycin in Lyme borreliosis: discrepant results of an in vitro and in vivo animal susceptibility study and a clinical trial in patients with erythema migrans. Acta Derm Venereal 72: 297-300.
125. Krbkova L, Stanek G. (1996) Therapy of Lyme borreliosis in children. Infection 24: 170-173.
126. Ablashi DV et al. (1998) Human Herpesvirus-6 (HHV-R) infection in multiple sclerosis: a preliminary report [In Process Citation]. Mult Scler 4: 490-496.
127. Becker KG et al. (1997) Analysis of a sequenced cDNA library from multiple sclerosis lesions. J Neuroimmunol 77: 27-38.
128. Clausen J, Hoff-Jorgensen R, Rasmussen HB. (1990) Antibody reactivity against animal retroviruses in multiple sclerosis. Acta Neurol Scand 81: 223-228.
129. Cook SD, Dowling PC. (1980) Multiple sclerosis and viruses: an overview. Neurology 30: 80-91.
130. Gorelick PB. (1989) Clues to the mystery of multiple sclerosis. Postgrad Med 85: 125-128, 131-124.
131. Haahr S et al. (1994) A putative new retrovirus associated with multiple sclerosis and the possible involvement of Epstein-Barr virus in this disease. Ann NY Acad Sci 724: 148-156.
132. Haahr S et al. (1995) Increased risk of multiple sclerosis after late Epstein-Barr virus infection: a historical prospective study. Mult Scler 1: 73-77.
133. Kurtzke JF. (1993) Epidemiologic evidence for multiple sclerosis as an infection [published erratum appears in Clin Microbiol Rev 1994 Jan; 7(1):141]. Clin Microbiol Rev 6: 382-427.
134. Link H et al. (1992) Virus-reactive and autoreactive T cells are accumulated in cerebrospinal fluid in multiple sclerosis. J Neuroimmunol 38: 63-73.
135. Martin JR. (1981) Herpes simplex virus types 1 and 2 and multiple sclerosis. Lancet 2: 777-781.
136. Martyn CN. (1997) Infection in childhood and neurological diseases in adult life. Br Med Bull 53: 24-39.
137. Martyn CN, Cruddas M, Compston DA. (1993) Symptomatic Epstein-Barr virus infection and multiple sclerosis. J Neurol Neurosurg Psychiatry 56: 167-168.
138. Munch M et al. (1997) The implications of Epstein-Barr virus in multiple sclerosis - a review. Acta Neurol Scand 169: (Suppl), 59-64.
139. Munch M et al. (1998) A single subtype of Epstein-Barr virus in members of multiple sclerosis clusters [In Process Citation]. Acta Neurol Scand 98: 395-399.
140. Rice GP. (1992) Virus-induced demyelination in man: models for multiple sclerosis. Curr Opin Neurol Neurosurg 5: 188-194.
141. Roos RP. (1983) Viruses and demyelinating disease of the central nervous system. Neurol Clin 1: 681-700.
142. Sanders VJ et al. (1996) Herpes simplex virus in postmortem multiple sclerosis brain tissue [see comments]. Arch Neurol 53: 125-133.
143. Sanders VJ et al. (1996) Detection of herpesviridae in postmortem multiple sclerosis brain tissue and controls by polymerase chain reaction. J Neurovirol 2: 249-258.
144. Sayetta RB. (1986) Theories of the etiology of multiple sclerosis: a critical review. J Clin Lab Immunol 21: 55-70.
145. Woyciechowska JL et al. (1985) Viral antibodies in twins with multiple sclerosis. Neurology 35: 1176-1180.
146. Inaba M et al. (1991) Distinct mechanisms of neonatal tolerance induced by dendritic cells and thymic B cells. J Exp Med 173: 549-559.
147. Forsthuber T, Yip H, Clehmann PV. (1996) Induction of TH1 and TH2 immunity in neonatal mice [see comments]. Science 271: 1728-1730.
148. Nango K et al. (1991) Ontogeny of thymic B cells in normal mice. Cell Immunol 133: 109-115.
149. Ridge JP, Fuchs EJ, Matzinger P. (1996) Neonatal tolerance revisited: turning on newborn T cells with dendritic cells [see comments]. Science 271: 1723-1726.
150. Wood KJ. (1996) New concepts in tolerance. Clin Transplant 10: 93-99.
151. Archard LC et al. (1987) The role of Coxsackie B viruses in the pathogenesis of myocarditis, dilated cardiomyopathy and inflammatory muscle disease. Biochem Soc Symp 53: 51-62.
152. Bowles NE et al. (1987) Dermatomyositis, polymyositis, and Coxsackie-B-virus infection. Lancet 1: 1004-1007.
153. Bowles NE et al. (1987) Coxsackie B myocarditis. Biomed Pharmacother 41: 197-198.
154. Oomes PG et al. (1995) Anti-GM1 IgG antibodies and Campylobacter bacteria in Guillain-Barre syndrome: evidence of molecular mimicry. Ann Neurol 38: 170-175.
155. Sovilla JY, Regli R, Francioli PB. (1988) Guillain-Barre syndrome following Campylobacter jejuni enteritis. Report of three cases and review of the literature. Arch Intern Med 148: 739-741.
156. Visser LH et al. (1996) Cytomegalovirus infection and Guillain-Barre syndrome: the clinical, electrophysiologic, and prognostic features. Dutch Guillain-Barre Study Group [see comments]. Neurology 47: 668-673.
157. Yuki N et al. (1993) A bacterium lipopolysaccharide that elicits Guillain-Barre syndrome has a GM1 ganglioside-like structure. J Exp Med 178: 1771-1775.
158. Schumacher GA. (1966) Multiple sclerosis. Arch Neurol 14: 571-573.